Whitehawk Therapeutics posts results for quarter ended Sept 30, 2025

Whitehawk Therapeutics reported that it issued a press release announcing financial results for the quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/06/2025 - 08:03 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Whitehawk Therapeutics reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1 and is incorporated by reference.

The company states the information under Item 2.02 and Item 9.01 (including Exhibit 99.1) is being furnished, not filed, and therefore is not subject to the liabilities of Section 18 of the Exchange Act, unless specifically incorporated by reference elsewhere.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did WHWK announce in this 8-K?

The company issued a press release announcing its financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1.

Is the press release considered filed or furnished?

It is furnished under Item 2.02 and Item 9.01 and is not deemed filed or subject to Section 18 liabilities unless specifically incorporated by reference.

Where can I find the detailed results for WHWK?

They are contained in the press release included as Exhibit 99.1.

What period do the results cover for WHWK (NASDAQ: WHWK)?

The press release covers the financial results for the quarter ended September 30, 2025.

What exhibits accompany this report?

Exhibit 99.1 (Press Release, dated November 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

On which exchange does WHWK trade?

WHWK common stock trades on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000142214200014221422025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Whitehawk Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38560	61-1547850
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2 Headquarters Plaza, East Building 11th Floor
Morristown, New Jersey				07960
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 551 321-2234

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value per share		WHWK		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Whitehawk Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
 

Exhibit Number						Description
99.1						Press Release, dated November 6, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			WHITEHAWK THERAPEUTICS, INC.
Date:	November 6, 2025	By:	/s/ Scott Giacobello
			Scott Giacobello Chief Financial Officer